Revolutionizing Life Sciences: Strateos Is Turning Labs into Smart Data Centers

In an era where innovation is synonymous with speed and scale, Strateos has emerged as a transformational force in life sciences. The company is pioneering the future of scientific discovery through remote access laboratories and advanced lab control software, redefining how research is conducted, scaled, and automated. Headquartered in the U.S., Strateos merges data science, AI, automation, and robotics to create intelligent lab infrastructures that function more like smart data centers than traditional wet labs. The result: faster, reproducible, and more insightful research that is not bound by geography, staffing limitations, or outdated workflows. Strateos’ vision is as clear as it is ambitious—turn biology into an information technology. At its core is the Strateos SmartLab Platform™, a robust, cloud-based ecosystem designed to streamline the design, execution, and analysis of scientific experiments. By integrating physical lab processes with digital control systems, the platform empowers researchers to manage entire workflows remotely, with a level of precision and consistency previously unachievable. This capability is not merely a technological leap; it’s a paradigm shift. In a domain where trial-and-error and time-consuming iterations have long defined the pace of discovery, Strateos replaces inefficiencies with clean, high-throughput, data-driven experimentation.

The Power of Cloud-Connected Automation

Strateos’ SmartLabs are not aspirational—they’re operational. The company runs two fully automated cloud laboratories, accessible 24/7 from anywhere in the world. These labs combine advanced robotics, imaging, mass spectrometry, and AI-powered analytics to support a wide range of research disciplines, from synthetic biology and medicinal chemistry to tissue analytics. These on-demand facilities provide seamless access to researchers and pharma partners alike, enabling them to run experiments without being physically present. This is particularly vital in a post-pandemic era where remote collaboration and distributed R&D models are fast becoming the norm. The company also offers the flexibility for organizations to deploy the Strateos platform within their own labs—whether automated or not—effectively turning any life science lab into a digital-first operation.

Pioneering AI-Driven Drug Discovery

One of Strateos’ most powerful applications lies in its AI-powered drug discovery workflows. The platform automates entire cycles of compound synthesis, screening, and testing—creating closed-loop systems that drastically reduce the time from target identification to lead optimization. By integrating phenotypic, biochemical, mass spec, ADME, genomic, and imaging datasets, Strateos enables pharma companies to harness the full potential of machine learning. Their APIs are secure and scalable, allowing interoperability with existing data engineering pipelines, enhancing reproducibility, and unlocking new dimensions in computational biology. This end-to-end approach means that pharmaceutical partners can transition from hypotheses to actionable insights at an unprecedented pace—critical in a competitive drug development landscape where time-to-market often defines success.

End-to-End Capabilities in Discovery Biology and Chemistry

Strateos offers an integrated portfolio that spans discovery biology, small molecule R&D, and tissue analytics. Their discovery biology services allow clients to run cellular assays, imaging protocols, and bioanalytical workflows entirely in the cloud. Scientists gain access to high-throughput capabilities without needing to invest in physical infrastructure or manage complex logistics. In small molecule discovery, Strateos supports everything from hit identification to lead optimization. Their medicinal chemistry engine enhances the design-make-test-analyze cycle through continuous automation and remote orchestration, significantly accelerating early-stage drug development. The company’s innovations in tissue technology further broaden its scientific scope. By applying high-throughput tissue sectioning and automated imaging to pathological samples, researchers can detect molecular and cellular disruptions at earlier stages of disease progression—crucial for targeted intervention and precision medicine.

Visionary Leadership at the Helm

Much of Strateos’ success is credited to the strategic foresight of Mark Fischer-Colbrie, the company’s President and CEO. With more than three decades of experience across diagnostics, medical devices, therapeutics, and lab automation, Fischer-Colbrie brings a rare combination of technical fluency and operational excellence. Previously the CEO of Labcyte Inc.—a company known for pioneering acoustic dispensing—he led multiple IPOs and filed several patents during his tenure at various biotech firms. A Stanford graduate with an MBA from UC Berkeley, Fischer-Colbrie has been recognized nationally, including being named Ernst & Young’s Entrepreneur of the Year (Life Sciences) in Northern California. Beyond corporate milestones, he is a committed contributor to the scientific community, serving as Chairman of JDRF’s International Board and a long-standing member of the Analytical, Life Sciences & Diagnostics Association (ALDA). Under his leadership, Strateos continues to shape the future of automated science.

Redefining the Lab of the Future

As the life sciences industry grapples with soaring R&D costs, talent shortages, and the growing complexity of data analysis, Strateos stands as a blueprint for the lab of the future. Its SmartLab Platform offers not just automation, but orchestration—bridging siloed datasets, connecting distributed teams, and elevating the standard of scientific discovery. By removing geographic constraints and embedding computation at every layer of research, Strateos makes biology as programmable and scalable as software. It is not simply enabling remote experimentation; it is pioneering a future where discovery is frictionless, data-rich, and exponentially faster. In an age where science must move at the speed of global challenges, Strateos is delivering the infrastructure to make it possible.

Mark Fischer-Colbrie, President & CEO

“The Strateos SmartLab Platform™ helps scientists more efficiently and reproducibly design, run, and analyze experiments to achieve new and faster scientific discoveries.”